ROCKVILLE, Md., Sept. 1, 2009 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that Dr. Raafat Fahim, President and Chief Executive Officer will present at the Rodman & Renshaw Annual Global Investment Conference held on September 9-11, 2009 at the New York Palace Hotel in New York, NY. Dr. Fahim's presentation is scheduled for Thursday, September 10, 2009 at 3:15 p.m., EDT.

You can access the web cast of this presentation on the company's "Events and Webcasts" page at www.nabi.com or at http://www.wsw.com/webcast/rrshq15/nabi .

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(r) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and PentaStaph(tm) (Pentavalent S. aureus Vaccine), a vaccine designed to protect against the most dangerous and prevalent strains of S. aureus bacterial infections. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit our Web site:http://www.nabi.com.

CONTACT:  Nabi Biopharmaceuticals
          Investor Relations
          301-770-3099
          www.nabi.com